Fibromyalgia Study In Adults
Launched by GLAXOSMITHKLINE · Nov 21, 2005
Trial Information
Current as of May 17, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Diagnosis of primary fibromyalgia as defined by the American College of Rheumatology (ACR).
- • Females of childbearing potential will only be eligible if taking adequate contraceptive measures.
- • Other co-existent chronic pain conditions such as osteoarthritis, will not exclude the subject if the pain associated with the condition is less severe than the pain of fibromyalgia.
- • Only subjects experiencing moderate/severe pain (pain intensity score \>= 4 on the pain numerical rating scale) will be eligible for this study.
- • Subjects that are generally well.
- • Have the ability to discontinue prohibited medications for the duration of the study.
- Exclusion criteria:
- • Subjects with 'flare' of arthritic conditions.
- • Evidence of clinically significant medical conditions including cardiovascular conditions (e.g. postural hypotension, and raised blood pressure, ECG abnormalities).
- • History of drug and/or alcohol abuse or major depression.
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Milano, Lombardia, Italy
Kuopio, , Finland
Roma, Lazio, Italy
Benevento, Campania, Italy
Bruxelles, , Belgium
Mikkeli, , Finland
Truro, Cornwall, United Kingdom
Heidelberg, Baden Wuerttemberg, Germany
Diepenbeek, , Belgium
Huettenberg, Hessen, Germany
Zwolle, , Netherlands
Jyvaskyla, , Finland
Cambridge, Cambridgeshire, United Kingdom
Frederiksberg, , Denmark
Merksem, , Belgium
Lomme, , France
Paris, , France
Fellbach, Baden Wuerttemberg, Germany
Bad Hersfeld, Hessen, Germany
Mölndal, , Sweden
Poole, Dorset, United Kingdom
Patients applied
Trial Officials
GSK Clinical Trials
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials